HighGravityDataCurrent guidance
9 items
Dow
Guidance from Dow’s last 8 earnings releases. Every value links to its sentence in the filing. See something wrong? Tell us.
Releases tracked
8
Latest release
Jul 23, 2026
Data checked
Jul 23, 2026
What changed in the Jul 23, 2026 release
Each item compared with the same item in the previous release (Apr 23, 2026). Values in quotation marks are the company’s words.
New — first stated in this releaseRaised / Lowered / Narrowed / Widened — changed from the prior releaseRevised — wording changed, direction not determinableChanged — value changed; the comparison couldn’t be parsed to a directionReiterated — restated unchangedNot restated — stated before, absent nowRaised and lowered describe the number, not whether the change is favorable.
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| New | Benefits from Transform to Outperform | for FY2026 | — | “approximately $200 million more” | Filing ↗ |
| New | Incremental benefits from Transform to Outperform this year | for FY2026 | — | “approximately $200 million more” | Filing ↗ |
| New | Total in-year benefits from self-help | for FY2026 | — | “greater than $1.3 billion” | Filing ↗ |
| New | Total in-year benefits from self-help initiatives | for FY2026 | — | “greater than $1.3 billion” | Filing ↗ |
Show 8 items not restated in this release
| Change | Metric | Period | Previous | Now | Source |
|---|---|---|---|---|---|
| Not restated | Underlying earnings | for FY2030 | “more than $3 billion” | — | Filing ↗ |
| Not restated | Underlying earnings from counter-cyclical growth investments | for FY2030 | “more than $3 billion” | — | Filing ↗ |
| Not restated | Near-term cash support and earnings growth levers | for FY2026 | “more than $6 billion” | — | Filing ↗ |
| Not restated | Additional earnings from Transform to Outperform | No period stated | “at least $2 billion” | — | Filing ↗ |
| Not restated | Targeted cost reductions | for FY2026 | “$1 billion” | — | Filing ↗ |
| Not restated | Targeted cost savings | for FY2026 | “at least $1 billion” | — | Filing ↗ |
| Not restated | Cash support actions | No period stated | “approximately $6 billion” | — | Filing ↗ |
| Not restated | Near-term cash support | No period stated | “more than $6.5 billion” | — | Filing ↗ |
Current guidance
Guidance for periods that have not yet ended, at its most recent value, grouped by horizon.
Current fiscal year
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Near-term cash support and earnings growth levers | “more than $6 billion” | for FY2026 | Company-defined | Jul 24, 2025 | 1 | Filing ↗ |
| Benefits from Transform to Outperform | “approximately $200 million more” | for FY2026 | Company-defined | Jul 23, 2026 | 1 | Filing ↗ |
| Incremental benefits from Transform to Outperform this year | “approximately $200 million more” | for FY2026 | Company-defined | Jul 23, 2026 | 1 | Filing ↗ |
| Targeted cost reductions | “$1 billion” | for FY2026 | Company-defined | Oct 23, 2025 | 1 | Filing ↗ |
| Targeted cost savings | “at least $1 billion” | for FY2026 | Company-defined | Apr 24, 2025 | 1 | Filing ↗ |
| Total in-year benefits from self-help | “greater than $1.3 billion” | for FY2026 | Company-defined | Jul 23, 2026 | 1 | Filing ↗ |
| Total in-year benefits from self-help initiatives | “greater than $1.3 billion” | for FY2026 | Company-defined | Jul 23, 2026 | 1 | Filing ↗ |
Next year and medium term
Long term
| Metric | Current value | Period | Measure | First stated | Times stated | Source |
|---|---|---|---|---|---|---|
| Dividend | “targeting a competitive dividend across the economic cycle” | for the long term | Declared action | Jul 24, 2025 | 1 | Filing ↗ |
How one item moved
Near-term cash support, No period stated — every statement across the year, each linked to its filing.
How your Specialty chemicals sector group guides
12 companies in Specialty chemicals. What they guide on, and who reported this season.
Most-guided metric families
This season’s releases
| RPM International | Oct 6, 2026 | 5 changes |
| Albemarle | Aug 5, 2026 | 24 changes |
| DuPont | Aug 4, 2026 | 11 changes |
| Cabot Corporation | Aug 3, 2026 | 4 changes |
| Eastman Chemical | Jul 30, 2026 | 9 changes |
| Huntsman | Jul 30, 2026 | 1 change |
| FMC Corporation | Jul 29, 2026 | 34 changes |
| Ashland | Jul 28, 2026 | 4 changes |
Get this for your own peer set — Peer Guidance Briefing, $3,000.
Full history
Every metric, every release, eight quarters — the complete record as one table.
| Metric | FY2030 | FY2026 | FY2025 | Long-term | No period |
|---|---|---|---|---|---|
| Additional earnings from Transform to Outperform | — | — | — | — | 1 statement |
| Additional near-term earnings | — | — | — | — | 1 statement |
| Near-term cash support and earnings growth levers | — | 1 statement | — | — | — |
| Underlying earnings | 1 statement | — | — | — | — |
| Underlying earnings from counter-cyclical growth investments | 1 statement | — | — | — | — |
The full record for Dow and its Specialty chemicals peers, delivered as a Peer Guidance Briefing — PDF and Excel, every value linked to its filing.
Filings
The 8 earnings releases this page is built from.
| Filed | Fiscal period | Accession | Guidance items | |
|---|---|---|---|---|
| Jul 23, 2026 | FY2026 Q2 | 0001751788-26-000144 | 4 | Open filing ↗ |
| Apr 23, 2026 | FY2026 Q1 | 0001751788-26-000131 | 0 | Open filing ↗ |
| Jan 29, 2026 | FY2025 Q4 | 0001751788-26-000011 | 4 | Open filing ↗ |
| Oct 23, 2025 | FY2025 Q3 | 0001751788-25-000153 | 3 | Open filing ↗ |
| Jul 24, 2025 | FY2025 Q2 | 0001751788-25-000142 | 2 | Open filing ↗ |
| Apr 24, 2025 | FY2025 Q1 | 0001751788-25-000125 | 12 | Open filing ↗ |
| Jan 30, 2025 | FY2024 Q4 | 0001751788-25-000005 | 4 | Open filing ↗ |
| Oct 24, 2024 | FY2024 Q3 | 0001751788-24-000147 | 2 | Open filing ↗ |
Values in quotation marks are the company’s words; the classification and filing links are HighGravityData’s. HighGravityData does not score or rank companies or give investment advice.
Report an error